ICC Tribunal Awards AOP Health €112 Million in PharmaEssentia BESREMi Dispute
Stories are grouped across languages, rewritten into a fixed editorial format, and linked to original sources.
TL;DR
- ICC tribunal awarded AOP Health about €112 million against PharmaEssentia.
- Damages cover intentional contract breaches and excessive pricing for BESREMi.
- PharmaEssentia's counterclaims were dismissed.
- German court review of earlier partial award is ongoing.
Overview
An ICC arbitral tribunal rendered a final award in favor of AOP Orphan Pharmaceuticals GmbH (AOP Health) against PharmaEssentia Corp., quantifying damages from a dispute over pricing and contractual breaches related to the medicine BESREMi.
What Happened
On August 8, 2026, an arbitral tribunal under the ICC rendered a final award in the ongoing dispute between AOP Health and PharmaEssentia concerning BESREMi (ropeginterferon alfa-2b).
The tribunal awarded AOP Health approximately €82 million in damages for intentional contractual breaches by PharmaEssentia, plus about €31 million as reimbursement for overpayments due to excessive pricing between 2019 and 2022.
The tribunal confirmed that PharmaEssentia overcharged AOP Health by up to 900% over several years and validated AOP Health's compensation of profit-sharing payments against owed damages.
All claims filed by PharmaEssentia during the damages quantification stage were dismissed, and as a result, AOP Health does not owe any payment to PharmaEssentia. Interest on AOP Health's claims will continue to accrue until payment is made by PharmaEssentia.
The tribunal decision follows a partial award from February 2025, which established PharmaEssentia's liability, and subsequent German court review proceedings regarding the partial award are ongoing.
Context
The dispute centers on the pharmaceutical product BESREMi, a treatment for rare blood cancers, for which AOP Health holds development and commercialization rights in Europe, the CIS, and the Middle East.
Previous ICC tribunal awards and related German court proceedings have addressed contract termination attempts and liability, while the latest award focuses on damages quantification.
Why It Matters
- The award quantifies and finalizes damages in a long-running pharmaceutical licensing dispute, clarifying financial liability and limiting AOP Health's obligations to PharmaEssentia.
- The decision may affect ongoing and future distribution, pricing, and licensing arrangements for BESREMi in Europe and other covered territories.
- The outcome highlights the role of ICC arbitration in resolving complex contractual disputes in the pharmaceutical sector.